The incidence of bloodstream infections caused by Candida species has increased dramatically, so that these organisms now account for 10% of all nosocomial bloodstream isolates. Similarly, mucocutaneous candidal infections are becoming increasingly problematic; 80% of patients with the acquired immunodeficiency syndrome (AIDS) have one or more candidal infections. Adherence to epithelial cells is a critical step in the colonization of mucosal surfaces by the organisms and the subsequent establishment of mucocutaneous infection. Analogously, for hematogenous dissemination to occur, the adherence of Candida species to intravascular structures is required for blood-borne organism to egress from the intravascular compartment and invade target organs. Because the mortality rates associated with candidal infections remain disturbingly high despite the presence of antifungal agents with excellent activity against Candida species, optimal therapy will necessitate therapies that increase host resistance to candidal infection (such as blocking adherence), combined with the use of antifungal agents. Since adherence is a critical early step in the development of candidal infections, we will identify and characterize adhesins of Candida albicans by cloning the genes that encode them in Saccharomyces cerevisiae. We already have transformed non-adherent S. cerevisiae with candidal DNA and have isolated a clone that expresses a candidal adhesin. In this proposal we will characterize this adherence gene and its products by constructing mutants of C. albicans in which both alleles of the adherence gene has been deleted. The ability of these mutants to adhere to endothelial and epithelial cells, and their virulence in murine models of hematogenously disseminated and mucosal candidiasis will be determined. The candidal adhesin that we have identified will be purified and its function characterized biochemically; it will be tested further as a potential immunogen. Transformed S. cerevisiae that express additional candidal adhesins will be identified using the diverse selection procedures. These adhesins will be analyzed similarly to the one already identified. The ultimate goal of these investigations is to develop therapeutic strategies to block candidal adherence to host cells. These strategies may then become applicable to both the treatment and prevention of candidal infections.

Project Start
1997-01-01
Project End
1997-12-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
City
Torrance
State
CA
Country
United States
Zip Code
90502
Boxx, Gayle M; Kozel, Thomas R; Nishiya, Casey T et al. (2010) Influence of mannan and glucan on complement activation and C3 binding by Candida albicans. Infect Immun 78:1250-9
Boxx, Gayle M; Nishiya, Casey T; Kozel, Thomas R et al. (2009) Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol Immunol 46:473-80
Zhang, Mason X; Bohlman, M Charlotte; Itatani, Carol et al. (2006) Human recombinant antimannan immunoglobulin G1 antibody confers resistance to hematogenously disseminated candidiasis in mice. Infect Immun 74:362-9
Lillegard, Joseph B; Sim, Robert B; Thorkildson, Peter et al. (2006) Recognition of Candida albicans by mannan-binding lectin in vitro and in vivo. J Infect Dis 193:1589-97
Granger, Bruce L; Flenniken, Michelle L; Davis, Dana A et al. (2005) Yeast wall protein 1 of Candida albicans. Microbiology 151:1631-44
Ibrahim, Ashraf S; Spellberg, Brad J; Avenissian, Valentina et al. (2005) Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect Immun 73:999-1005
Spellberg, Brad J; Ibrahim, Ashraf S; Avenissian, Valentina et al. (2005) The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect Immun 73:6191-3
Toenjes, Kurt A; Munsee, Suzanne M; Ibrahim, Ashraf S et al. (2005) Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 49:963-72
Cutler, J E (2005) Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5:383-92
VandenBerg, Alysia L; Ibrahim, Ashraf S; Edwards Jr, John E et al. (2004) Cdc42p GTPase regulates the budded-to-hyphal-form transition and expression of hypha-specific transcripts in Candida albicans. Eukaryot Cell 3:724-34

Showing the most recent 10 out of 63 publications